BDGENE key facts
- Developer of gene therapy drugs designed to cure eye diseases.
- It has raised $40.0M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Innoangel Fund, Lapam Capital, Shenzhen Yifeng Investment Management Enterprise, Tsinghua Holdings Capital, Ennovation Ventures — 12 tracked in total.
- Status: Privately Held (backing).
Who backs BDGENE
12+- ·The complete investor list: 12 names
- ·Watch BDGENE: the Monday email on marks, rounds and moves
BDGENE funding rounds
No funding rounds for BDGENE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BDGENE investors
12 investors are on record for BDGENE, including Innoangel Fund, Lapam Capital, Shenzhen Yifeng Investment Management Enterprise and Tsinghua Holdings Capital.
About BDGENE
Developer of gene therapy drugs designed to cure eye diseases. The company offers gene editing, oncolytic virus platforms, lentiviral vectors, and gene delivery tools, enabling ophthalmologists to treat diabetic macular degeneration, age-related macular degeneration, and herpes simplex keratitis with improved precision and efficacy.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- bdgenetherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
BDGENE doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.